ABBVIE HIGHLIGHTS POSITIVE RESULTS FROM THE PHASE 2 APEX PART B STUDY OF ZUMILOKIBART IN MODERATE TO SEVERE ATOPIC DERMATITIS, AS A LATE BREAKER AT EADV 2026

Reuters · 3d ago

Please log in to view news